Clovis Oncology (XTRA:C6O) - Cours de l'action, nouvelles et analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

C6O Aperçu des actions

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Plus de détails

C6O analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	2/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 48.64% par an

Les revenus ont augmenté 5.6% par an au cours des 5 dernières années

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

Les actions sont très illiquides

Capitaux propres négatifs

A moins d'un an de piste de trésorerie

N'a pas de capitalisation boursière significative ( €14M )

+ 1 plus de risques

Clovis Oncology, Inc. Concurrents

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Paion

XTRA:PA8

€2.6m

Epigenomics

XTRA:ECX

€616.0k

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Clovis Oncology
Historique des cours de bourse
Prix actuel de l'action	US$0.091
Plus haut sur 52 semaines	US$3.00
Plus bas sur 52 semaines	US$0.09
Bêta	0.95
1Variation sur 1 mois	0%
Variation sur 3 mois	0%
Variation sur 1 an	-94.05%
3Variation sur 3 ans	-97.84%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-99.87%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	C6O	DE Biotechs	DE Marché
7D	0%	0.8%	0.8%
1Y	-94.1%	-18.3%	8.6%

Rendement vs Industrie: C6O a sous-performé le secteur German Biotechs qui a rapporté -18.3 % au cours de l'année écoulée.

Rendement vs marché: C6O a sous-performé le marché German qui a rapporté 8.6 % au cours de l'année écoulée.

Volatilité des prix

Is C6O's price volatile compared to industry and market?
C6O volatility
C6O Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de C6O a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de C6O au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Clovis Oncology se comparent-ils à sa capitalisation boursière ?
C6O statistiques fondamentales
Capitalisation boursière	€12.78m
Bénéfices(TTM)	-€233.87m
Recettes(TTM)	€123.50m

0.1x

Ratio P/S

-0.1x

Ratio P/E

Le site C6O est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
C6O compte de résultat (TTM)
Recettes	US$133.02m
Coût des recettes	US$31.59m
Marge brute	US$101.43m
Autres dépenses	US$353.33m
Les revenus	-US$251.91m

Derniers bénéfices déclarés

Sep 30, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.74
Marge brute	76.25%
Marge bénéficiaire nette	-189.37%
Ratio dettes/capitaux propres	-158.0%

Quelles ont été les performances à long terme de C6O?

Voir les performances historiques et les comparaisons

This company listing is no longer active

C6O Aperçu des actions

Récompenses

Analyse des risques

Clovis Oncology, Inc. Concurrents

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

XTRA:PA8

€2.6m

XTRA:ECX

€616.0k

Historique des prix et performances

Nouvelles et mises à jour récentes

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Clovis Oncology, Inc. Résumé des fondamentaux

0.1x

-0.1x

Bénéfices et recettes